杭州奥泰生物技术股份有限公司 关于独立董事公开征集委托投票权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要提示： 根据中国证券监督管理委员会颁布的《上市公司股权激励管理办法》及《公 开征集上市公司股东权利管理暂行规定》（以下简称"《暂行规定》"）的有关 规定，杭州奥泰生物技术股份有限公司（以下简称"公司"或"本公司"）独立 董事周亚力受其他独立董事的委托作为征集人，就公司拟于 2024 年 5 月 30 日召 开的 2023 年年度股东大会审议的股权激励计划相关议案向公司全体股东征集委 托投票权。 一、征集人的基本情况、对表决事项的表决意见及理由 证券代码：688606 证券简称：奥泰生物 公告编号：2024-020 州奥泰生物技术股份有限公司章程》（以下简称"《公司章程》"）中规定的不 得担任公司董事的情形。 3、征集人承诺不存在《暂行规定》第三条规定的不得作为征集人公开征集 投票权的情形，并在征集日至行权日期间将持续符合作为征集人的条件。本次征 集行动完全基于征集人作为上市公司独立董事的职责，所发布信息未 ...

（一）审议通过《关于公司<2024 年限制性股票激励计划（草案）>及其摘 要的议案》； 证券代码：688606 证券简称：奥泰生物 公告编号：2024-018 杭州奥泰生物技术股份有限公司 第三届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 杭州奥泰生物技术股份有限公司（以下简称"公司"）第三届董事会第四次 会议（以下简称"本次会议"）于 2024 年 5 月 14 日下午 14：00 在公司会议室 以现场与通讯相结合的方式召开。董事长高飞先生在会议上就紧急召开本次会议 的情况进行了说明，公司全体董事均同意豁免本次董事会会议通知时限要求。本 次会议由公司董事长高飞先生召集并主持，本次会议应出席董事 5 名，实际出席 董事 5 名，高级管理人员列席了本次会议。本次会议的召集、召开程序和方式符 合《中华人民共和国公司法》（以下简称"《公司法》"）等法律法规以及《杭 州奥泰生物技术股份有限公司章程》（以下简称"《公司章程》"）的有关规定， 会议决议合法、有效。 二、董事会会议审 ...

会议由监事会主席高跃灿先生主持召开，全体与会监事经认真审议和表决， 形成以下决议： 1、审议通过《关于公司<2024 年限制性股票激励计划（草案）>及其摘要 的议案》 监事会认为：公司《2024 年限制性股票激励计划（草案）》及其摘要的内 容符合《公司法》《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公 司股权激励管理办法》（以下简称"《管理办法》"）、《上海证券交易所科创板 股票上市规则》（以下简称"《上市规则》"）、《科创板上市公司自律监管指南第 4 号——股权激励信息披露》等有关法律、行政法规、规范性文件以及《公司 章程》的规定。实施本次限制性股票激励计划有利于公司的持续发展，不存在 损害公司及全体股东利益的情形。 综上，监事会同意实施 2024 年限制性股票激励计划。 议案表决情况：本议案有效表决票 3 票，同意 3 票、反对 0 票、弃权 0 票。 证券代码：688606 证券简称：奥泰生物 公告编号：2024-017 杭州奥泰生物技术股份有限公司 第三届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性 ...

杭州奥泰生物技术股份有限公司监事会 关于 2024 年限制性股票激励计划（草案）的核查意见 杭州奥泰生物技术股份有限公司（以下简称"公司"）监事会依据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、《科创板 上市公司自律监管指南第 4 号——股权激励信息披露》（以下简称"《自律监管 指南》"）等相关法律、法规及规范性文件和《杭州奥泰生物技术股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，对公司《2024 年限制性股票 激励计划（草案）》（以下简称"《激励计划（草案）》"或"本激励计划"）及其 他相关资料进行了核查，发表核查意见如下： 1、公司不存在《管理办法》等法律、法规规定的禁止实施股权激励计划的 情形，包括： （1）最近一个会计年度财务会计报告被注册会计师出具否定意见或者无法 表示意见的审计报告； （2）最近一个会计年度财务报告内部控制被注册会计师出具否定意见或无 法表示意见的审计报告； （3）上市后最近 36 ...

!"#$%&'()*+,-./01 23456789:;<=+,/01 2023>?@ABCDEFG1 根据《证券发行上市保荐业务管理办法》、《上海证券交易所科创板股票上市 规则》等有关法律法规的规定，申万宏源证券承销保荐有限责任公司（以下简称 "申万宏源承销保荐"或"保荐机构"）作为杭州奥泰生物技术股份有限公司 （以下简称"奥泰生物"、"公司"）持续督导阶段的保荐机构，负责奥泰生物 首次公开发行股票并在科创板上市后的持续督导工作，并出具2023年度持续督导 跟踪报告。 | 一、持续督导工作情况 | | --- | | 序号 | 工作内容 | 持续督导工作情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度， | 保荐机构已建立健全并有效执行了持续督 | | | 并针对具体的持续督导工作制定相应的工 | 导制度，并制定了相应的工作计划 | | | 作计划 根据中国证监会相关规定，在持续督导工 | | | 2 | | 保荐机构已与奥泰生物签订《保荐协议》， 该协议明确了双方在持续督导期间的权利 | | | 作开始前，与上市公司或相关当事人签署 | | | | 持续督导 ...

Financial Performance - The company reported a total distributable profit of RMB 1,543,614,030.10 as of December 31, 2023[7]. - A cash dividend of RMB 15 per 10 shares (including tax) is proposed, totaling RMB 116,290,218.00, which represents 64.40% of the net profit attributable to shareholders in the consolidated financial statements for 2023[7]. - The company's operating revenue for 2023 was approximately ¥754.70 million, a decrease of 77.73% compared to ¥3.39 billion in 2022[24]. - Net profit attributable to shareholders for 2023 was approximately ¥180.58 million, down 84.76% from ¥1.18 billion in 2022[24]. - The net cash flow from operating activities decreased by 98.18%, amounting to approximately ¥24.76 million, compared to ¥1.36 billion in 2022[24]. - Basic earnings per share for 2023 were ¥2.28, a decline of 84.75% from ¥14.95 in 2022[25]. - The total assets at the end of 2023 were approximately ¥4.12 billion, a decrease of 12.33% from ¥4.69 billion at the end of 2022[24]. - The net assets attributable to shareholders decreased by 8.14% to approximately ¥3.83 billion from ¥4.17 billion at the end of 2022[24]. Revenue and Growth - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY for the fiscal year 2023, representing a growth of 15% year-over-year[17]. - User data showed an increase in active users by 25%, reaching 500,000 users by the end of 2023[18]. - The company provided a positive outlook for 2024, projecting a revenue growth of 20% based on new product launches and market expansion strategies[17]. - The company aims to launch three new products in the next fiscal year, which are anticipated to contribute an additional 200 million CNY in revenue[17]. - Revenue from infectious disease testing products reached 275 million RMB, with a growth rate of 41.52%[37]. - Excluding the impact of COVID-19 testing products, the company's main operating revenue grew by 26.91% year-on-year[28]. Research and Development - Investment in R&D increased by 30%, focusing on the development of new diagnostic technologies and products[18]. - The company's R&D expenditure as a percentage of operating revenue increased to 16.06%, up 9.94 percentage points from 6.12% in 2022[25]. - R&D investment amounted to 121 million RMB, accounting for 16.06% of operating revenue[38]. - The company has developed 25 new raw materials, including 18 domestically innovative raw materials, reinforcing its leading position in the global diagnostic reagent industry[58]. - The company is actively involved in the development of reagents for cancer markers, which is essential for early detection and treatment[47]. Product Development and Innovation - The company has launched over 1,200 products, covering various testing areas such as drug abuse detection and infectious disease testing, showcasing a diverse product line[98]. - The company has developed a range of biomarkers for various medical conditions, including inflammation, cardiac, anemia, hormone, thyroid function, tumor markers, diabetes, and preeclampsia, with most projects now in mass production[77]. - The company has successfully industrialized small diagnostic instruments such as electronic pregnancy test sticks, hemoglobin analyzers, and blood lipid analyzers, enhancing detection accuracy and coverage[78]. - The company has established eight core technology platforms, including biobased raw materials and POCT rapid diagnostics, all of which are independently developed and have reached maturity[70]. - The company has developed rapid testing reagents for drug abuse, including THC and cocaine, reflecting a focus on addressing substance abuse issues[47]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[17]. - The company is exploring partnerships with international firms to enhance its distribution network and increase sales channels[18]. - The company has a strong international market presence, with products sold in over 160 countries and regions, particularly excelling in the European market for drug testing products[59]. - The company aims to become a global leader in IVD solutions by continuously providing accurate and effective products and services[166]. - The company plans to enhance its R&D capabilities and attract high-level professionals to build an excellent innovation team[166]. Governance and Compliance - The company received a standard unqualified audit report from its accounting firm[6]. - The board of directors has approved the profit distribution plan, pending approval at the annual general meeting[8]. - The company has established a governance structure that ensures orderly operation of its business activities[171]. - The company is committed to strict compliance with the Company Law and regulatory rules, ensuring diligent and responsible conduct in all committee activities[199]. - The audit committee held 6 meetings during the reporting period, discussing key financial reports and budgets, including the 2022 annual report and the 2023 first-quarter report[198]. Risks and Challenges - The company emphasizes the importance of risk factors that may adversely affect its operations, as detailed in the management discussion and analysis section[5]. - The company faces risks related to product registration, as changes in regulations may hinder timely certification and market entry[106]. - The company is facing uncertainties regarding the ability of ODM customers to meet the new regulatory requirements under IVDR, which may affect future collaborations[116]. - The company has significant exposure to foreign exchange risks, with over 90% of its revenue derived from overseas sales, primarily settled in USD and EUR[110]. Shareholder and Executive Management - The total remuneration for the chairman was reported at 101.18 million yuan, reflecting the company's commitment to rewarding leadership[179]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 3.4556 million RMB[188]. - The company confirmed the appointment of its auditing firm for the 2023 fiscal year, ensuring compliance and transparency in financial reporting[179]. - The company reported a significant increase in shareholdings for key executives, with the chairman's shares increasing by 6,006,550 shares during the year[179]. - Changes in personnel included the resignation of independent directors Qiu Juanping and Xie Shilei, and the chairman of the supervisory board Chen Xiaoying due to term expiration[189].

Financial Performance - The company's operating revenue for Q1 2024 was CNY 199,920,896.28, representing a decrease of 15.34% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 44,788,913.62, an increase of 10.50% year-over-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 37,777,315.36, reflecting a growth of 30.83% compared to the previous year[5]. - Total operating revenue for Q1 2024 was CNY 199.92 million, a decrease of 15.3% compared to CNY 236.14 million in Q1 2023[20]. - Net profit for Q1 2024 increased to CNY 44.64 million, up 10.4% from CNY 40.34 million in Q1 2023[20]. - The net profit for Q1 2024 was CNY 51,953,066.44, representing an increase of 23.4% from CNY 42,088,665.76 in Q1 2023[29]. Cash Flow - Cash flow from operating activities showed a significant decline of 122.00%, amounting to CNY 39,081,462.52, primarily due to large payments made for supplier invoices from Q4 2022[6][9]. - Cash flow from operating activities for Q1 2024 was CNY 39.08 million, a significant improvement from a negative CNY 177.68 million in Q1 2023[23]. - The company reported a tax expense of CNY 2.51 million for Q1 2024, significantly lower than CNY 5.72 million in Q1 2023[20]. - The company received CNY 192.46 million in cash from sales and services in Q1 2024, an increase from CNY 158.89 million in Q1 2023[22]. - The ending balance of cash and cash equivalents was ¥927,567,931.18, down from ¥1,457,097,364.19 in Q1 2023[33]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,140,840,306.93, a slight increase of 0.60% from the end of the previous year[6]. - The company's total liabilities increased to RMB 298,053,605.46 from RMB 284,499,705.67, indicating a rise of approximately 4.5%[17]. - The total equity attributable to shareholders reached RMB 3,838,615,607.63, up from RMB 3,827,249,132.73, reflecting a growth of about 0.3%[17]. - The company's inventory decreased to RMB 161,875,508.42 from RMB 188,594,762.48, a reduction of about 14.2%[16]. - The accounts receivable decreased to RMB 87,785,816.55 from RMB 100,869,677.68, indicating a decline of approximately 13%[15]. - The company's total current assets of RMB 3,065,860,380.34, down from RMB 3,161,447,852.41, a decrease of about 3%[15]. Shareholder Information - The company had a total of 5,035 common shareholders at the end of the reporting period[12]. - The top shareholder, Hangzhou Jingguan Investment Management Co., Ltd., held 23.33% of the shares, totaling 18,492,600 shares[12]. Research and Development - R&D investment totaled CNY 23,156,697.04, down 35.89% year-over-year, with R&D expenses accounting for 11.58% of operating revenue, a decrease of 3.72 percentage points[6]. - R&D expenses decreased to CNY 20,881,044.76, a reduction of 37.8% from CNY 33,550,901.15 in Q1 2023[28]. Earnings Per Share - Basic and diluted earnings per share were both CNY 0.56, reflecting a year-over-year increase of 9.80%[6]. - Basic and diluted earnings per share for Q1 2024 were CNY 0.56, compared to CNY 0.51 in Q1 2023[21]. Financial Ratios - The weighted average return on net assets increased by 0.20 percentage points to 1.17%[6]. - The company’s total liabilities to equity ratio is approximately 0.078, indicating a low level of financial leverage[17].

证券代码：688606 证券简称：奥泰生物 公告编号：2024-016 杭州奥泰生物技术股份有限公司 关于召开 2023 年度暨 2024 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 05 月 16 日(星期四) 上午 11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 三、 参加人员 董事长、总经理：高飞先生 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 05 月 09 日(星期四)至 05 月 15 日(星期 三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 yanping.fu@alltests.com.cn 进行提问。公司将在说 明会上对投资者普遍关注的问题进行回答。 杭州奥泰生物技术股份有限公司（以下简称"公司"）已于 2024 年 ...

申万宏源证券承销保荐有限责任公司 关于杭州奥泰生物技术股份有限公司 2023年度募集资金存放与实际使用情况的核查意见 申万宏源证券承销保荐有限责任公司（以下简称"申万宏源承销保荐"或"保荐 机构"）作为杭州奥泰生物技术股份有限公司（以下简称"奥泰生物"或"公司"）首次 公开发行股票并在科创板上市及进行持续督导的保荐机构，根据《证券发行上市保 荐业务管理办法》、《上海证券交易所科创板股票上市规则》、《上市公司监管指引 第2号——上市公司募集资金管理和使用的监管要求（2022年修订）》和《上海证券交 易所科创板上市公司自律监管规则指引第1号——规范运作》等有关法律法规和规范性 文件的要求，对奥泰生物2023年度募集资金存放与使用情况进行了审慎核查，核 查意见如下： （一）实际募集资金金额、资金到账时间 根据中国证券监督管理委员会《关于同意杭州奥泰生物技术股份有限公司首 次公开发行股票注册的批复》(证监许可[2021]495 号)核准同意，公司首次公开发 行人民币普通股 13,500,000 股，发行价格 133.67 元/股，新股发行募集资金总额 为 1,804,545,000.00 元, 扣除发行费用 161, ...

根据《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 （以下简称"《规范运作》"）、《上市公司治理准则》《上海证券交易所科创板股票 上市规则》（以下简称"《股票上市规则》"）、《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）等法律、 法规、规范性文件，以及《杭州奥泰生物技术股份有限公司章程》（以下简称"《公 司章程》"）、《杭州奥泰生物技术股份有限公司董事会审计委员会工作细则》（以 下简称"《董事会审计委员会工作细则》"）等规则制度的相关规定，杭州奥泰生 物技术股份有限公司（以下简称"公司"）董事会审计委员会本着勤勉尽责的原 则，认真履行职责，现就 2023 年度工作情况报告如下： 一、董事会审计委员会基本情况 公司第二届董事会审计委员会成员由谢诗蕾（独立董事、会计专业人士）、 裘娟萍（独立董事）、陆维克（非独立董事）三名董事组成，其中谢诗蕾为主任 委员。因独立董事任期届满及相关法律法规要求，自 2023 年 11 月 23 日起，公 司第三届董事会审计委员会成员由周亚力（独立董事、会计专业人士）、郑展望 （独立董事）、赵华芳（非独立董 ...